Patents by Inventor Bas Van Der Woning

Bas Van Der Woning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Kv1.3 antibodies, and methods of production and use thereof
    Patent number: 11597763
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: March 7, 2023
    Assignee: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini, Alka Agrawal
  • ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF
    Publication number: 20190144538
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 16, 2019
    Applicant: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini